Reference
Pasau T, et al. Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma. Frontiers in Oncology 12: 7 Nov 2022. Available from: URL: http://doi.org/10.3389/fonc.2022.985446
Rights and permissions
About this article
Cite this article
Alectinib/crizotinib. Reactions Weekly 1938, 46 (2023). https://doi.org/10.1007/s40278-023-30187-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-30187-3